Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 286
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00251199 | VX-950 and Peginterferon for Hepatitis C | ||
| NCT01685801 | Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function | ||
| NCT02343445 | Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) | ||
| NCT01890772 | Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 | ||
| NCT01821963 | Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC) | ||
| NCT02070744 | Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion | ||
| NCT07022119 | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants | ||
| NCT01117012 | Rollover Study of VX-770 in Cystic Fibrosis Subjects | ||
| NCT01863238 | An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis | ||
| NCT04043806 | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | ||
| NCT06696443 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | ||
| NCT01726946 | A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C | ||
| NCT00923728 | A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors | ||
| NCT01216046 | Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects | ||
| NCT03277196 | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation | ||
| NCT00623649 | Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection | ||
| NCT02347657 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor | ||
| NCT01704521 | Viral Kinetics in HCV Clearance in Subjects With Hemophilia | ||
| NCT02508207 | A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT00493441 | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | ||
| NCT00865904 | Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation | ||
| NCT01262352 | Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation | ||
| NCT01052194 | A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis | ||
| NCT02871778 | Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia | ||
| NCT01144936 | Study of VX-985 in Subjects With Chronic Hepatitis C | ||
| NCT02445053 | Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) | ||
| NCT05153317 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older | ||
| NCT01897233 | Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT05324410 | A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants | ||
| NCT06147778 | Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis | ||
| NCT03304028 | MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique | ||
| NCT07231419 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | ||
| NCT05518734 | A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants | ||
| NCT01501383 | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy | ||
| NCT03061331 | Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation | ||
| NCT06529796 | Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment | ||
| NCT04340362 | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | ||
| NCT03224351 | A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis | ||
| NCT06747572 | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease | ||
| NCT04006873 | Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 | ||
| NCT05955872 | A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 | ||
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | ||
| NCT06508762 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 | ||
| NCT06794996 | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities | ||
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | ||
| NCT02392234 | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation | ||
| NCT05329649 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | ||
| NCT07624526 | Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty | ||
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | ||
| NCT04235140 | Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation |
